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Interferon regulatory factor-8 (IRF8) plays a crucial role in the transformation of microglia to a reactive
state by regulating the expression of various genes. In the present study, we show that IRF1 is required
for IRF8-induced gene expression in microglia. Peripheral nerve injury induced IRF1 gene upregulation in
the spinal microglia in an IRF8-dependent manner. IRF8 transduction in cultured microglia induced de
novo gene expression of IRF1. Importantly, knockdown of the IRF1 gene in IRF8-transduced microglia
prevented upregulation of interleukin-1b (IL-1b). Therefore, our ﬁndings suggest that expression of IL-1b
is dependent on IRF1 in IRF8-expressing reactive microglia.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Microglia are the principal immune cells and, therefore, the
major inﬂammatory mediators of the central nervous system (CNS)
(1,2). They play diverse roles in numerous CNS pathologies, such as
neuronal injury, trauma, ischemia, infection, and several neuro-
logical diseases. Under such pathological conditions, microglia
undergo a dramatic change in their gene expression pattern and
phenotypically transform into a reactive state, and thus become the
ﬁrst line of defense in the CNS (3,4). Reactive microglia produce
various proinﬂammatory cytokines such as interleukin-1b (IL-1b),
which has been shown to cause tissue inﬂammation (5,6) and
abnormal neuronal transmission (7). Therefore, chronic excessive
activation of microglia is considered to disrupt CNS homeostasis,and System Pharmacology,
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d/4.0/).which has been implicated in the pathogenesis of neurodegener-
ative diseases, such as Alzheimer's disease and multiple sclerosis,
and in neuropathic pain (2,8,9). However, the molecular mecha-
nisms for the control of such inﬂammatory reactive state of
microglia remain elusive.
Transcription factors are induced under pathological conditions
and may control the reactive state of microglia (9). We have pre-
viously shown that the transcription factor, interferon regulatory
factor-8 (IRF8), plays a crucial role in microglial activation as
demonstrated by the dramatic changes in the expression of a va-
riety of genes involved in microglial innate responses [toll-like re-
ceptor 2 (Tlr2)], chemotaxis [purinergic receptor P2Y12R (P2ry12)
and CX3 chemokine receptor CX3CR1 (Cx3cr1)], inﬂammatory
components [IL-1b (Il1b), cathepsin S (Ctss), and ATP-gated iono-
tropic receptor P2X4R (P2rx4)] (4). Notably, IRF8-expressing
microglia are involved in the pathogenesis of several neurological
diseases, including neuropathic pain (4) and multiple sclerosis (10).
Furthermore, we have also shown that IRF5 is upregulated in spinal
microglia after PNI in an IRF8-dependent manner, and is respon-
sible for direct transcriptional control of P2X4 receptor (11).
Therefore, the IRF8-mediated transcriptional network plays annese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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however, its mechanism of action is not fully understood.
IRF1 plays an important role in the inﬂammatory response (12)
and forms a complex with IRF8 that subsequently activates the
transcription of target genes (12). However, little is known about
the nature of IRF1 in microglia. Therefore, in the present study, we
explored the roles of IRF1 and its relationship with IRF8 in reactive
microglia.
Male IRF8-deﬁcient mice (Irf8/) and their wild-type litter-
mates, and C57BL/6 mice (Clea Japan, Japan) were used. All mice
used were aged 9e12 weeks at the start of each experiment, and
were housed in groups of two or three per cage at 22 ± 1 C under a
12-h lightedark cycle, and had access to food and water ad libitum.
All experimental procedures were performed under the guidelines
of Kyushu University.
We performed spinal nerve injury as previously described (4).
Extraction of total RNA was performed as previously described (4).
For reverse transcription, 150 ng of total RNA was transferred to the
reactionwith Prime Script reverse transcriptase (Takara, Japan). qRT-
PCR was performed using the 7500 real-time PCR system (Applied
Biosystems, Foster City, CA) with the Premix Ex Taq (Takara, Japan),
and the LightCycler 96 (Roche, Switzerland) with the FastStart
Essential DNA ProbesMaster (Roche, Switzerland). Expression levels
were normalized to the values for 18s ribosomal RNA.
Mice were deeply anesthetized and perfused transcardially with
phosphate-buffered saline (PBS) followed by ice-cold 4% para-
formaldehyde/PBS. The L4 segment of the lumbar spinal cord were
removed, postﬁxed in the same ﬁxative, and placed in 30% sucrose
solution for 24 h at 4 C. Transverse L4 spinal cord sections (30 mm)
were cut on a Leica CM 1850 cryostat and incubated for 2 h at room
temperature in a blocking solution (3% normal goat or donkey
serum), and then incubated for 48 h at 4 C in the primary antibody
for IRF1 (1:1000, Cell Signaling), IRF8 (1:500, Santa Cruz). Identi-
ﬁcation of cell types was performed using the following markers:
microglia, CD11b (1:1000, Serotec) and Iba1 (1:2000, Wako); as-
trocytes, GFAP (glial ﬁbrillary acidic protein, 1:1000, Chemicon);
neurons, NeuN (Neuronal Nuclei, 1:2000, Abcam). Spinal sections
were incubated with secondary antibodies conjugated to Alexa
Fluor™ 405, 488 or 546 (1:1000, Molecular Probes) andmounted in
VECTASHIELD with or without DAPI (Vector Laboratories). Three to
ﬁve sections from the L4 spinal cord segments of each mouse were
randomly selected and analyzed using an LSM510 Imaging System
(Carl Zeiss Japan).
We used lentiviral CS2 vectors (RIKEN, Japan) encoding mouse
IRF8-green ﬂuorescent protein (GFP), IRF8(K79E)-GFP, IRF1 or GFP
under the control of the human EF-1a promoter, or vectors
encoding Irf1 or control shRNA sequences expressed under the
control of H1 promoter. Each vector with pCAG-HIVgp (packaging
plasmid; RIKEN, Japan) and pCMV-VSV-G-RSV-Rev (RIKEN, Japan)
was cotransfected into HEK293T cells. After mixing with poly-
ethylene glycol, viral particles and 8 mg/ml polybrenewere added to
primary cultured microglia (1.2  105 cells/well), microglial BV2
cells (1.0  104 cells/well), astrocytic A1 cells (1.0  104 cells/well)
or neuronal Neuro2A cells (1.0  104 cells/well) contained in 24-
well plates.
All data are expressed as the mean ± SEM and were analyzed by
the Student's t test, two-way analysis of variance (ANOVA) followed
by the Bonferroni post hoc test, or one-way ANOVA with the Bon-
ferroni multiple comparison test or the Tukey's multiple compari-
son test. Statistical analysis was performed using GraphPad Prism
5.04 software. Signiﬁcance was reached at values of P < 0.05,
P < 0.01, or P < 0.001.
To examine the relationship between IRF1 and IRF8 inmicroglial
cells under in vivo condition, we investigated expressional pattern
of Irf1 in spinal cord of the PNI model mice in which the expressionof IRF8 is known to be increased in spinal microglia (4). We found
that Irf1 expressionwas markedly increased in the ipsilateral spinal
cord of wild-type (WT) PNI mice (Fig. 1A and B), whereas the other
IRFs (Irf2 and Irf3) were not altered (Fig. 1A and B). In these mice,
the Irf1 expression increased from 2 days, peaking at 7 days and
was maintained for more than 2 weeks after PNI (Fig. 1A), with a
time course matching that of IRF8 (4) (Fig. 1A). In contrast, no
detectable change was found in the contralateral spinal cord
(Fig. 1A). Notably, the PNI-induced upregulation of Irf1 was almost
completely suppressed in IRF8-deﬁcient (Irf8/) mice (Fig. 1B).
These results suggest that in the spinal cord after PNI, gene
expression of IRF1 is regulated by IRF8.
Although IRF8 expression is highly restricted in microglia in the
spinal cord (4), IRF1 has been shown to be ubiquitously expressed
in CNS cells including microglia, astrocytes, and neurons (13,14). To
determine the cell types showing increased IRF1 expression in the
spinal cord after PNI, we examined the localization of IRF1 protein
using an immunohistochemical approach. There were detectable
but weak signals of IRF1 immunoﬂuorescence in the contralateral
sides of the spinal cord (Fig. 1C). However, following PNI, IRF1
immunoﬂuorescence was markedly increased in the ipsilateral
spinal dorsal horn of WT mice (Fig. 1C). The increase in IRF1
immunoﬂuorescence was not observed in Irf8/mice (Fig. 1C). We
found that immunoﬂuorescence of IRF1 was observed in cells
labeled by CD11b, a microglia marker (Fig. 1C). In addition, some
IRF1 immunoﬂuorescence-positive cells were also labeled by GFAP
(an astrocytemarker) (Fig.1D). However, NeuN (a neuronal marker)
was not double-labeled with IRF1 (Fig. 1E). Furthermore, distinct
enhancement of IRF1 expression also occurred in the ipsilateral
ventral horn after PNI (Fig. 1FeH). Interestingly, in this region,
about half of cells positive to IRF1 immunoﬂuorescence were
observed in CD11b-positive microglia (Fig. 1F), and the others were
CD11b-negative cells including astrocytes (Fig. 1G). GFAP-positive
astrocytes did not express IRF8 (Fig. 1H). These results indicate
that, in the spinal cord after PNI, IRF1 expression is increased in
microglia as well as other cells including astrocytes, and is
dependent on IRF8-mediated signals.
To examine further mechanistic detail of the IRF8-mediated
IRF1 expression in microglia, IRF8-GFP gene was transduced into
primary cultured microglial cells. A GFP-encoding vector was used
as a control. We found that forced expression of IRF8 signiﬁcantly
increased the expression of Irf1 (Fig. 1I). The mutant IRF8 that is
formed by replacing lysine at amino acid position 79 with Glu
[IRF8(K79E)] resulting in a lack of DNA binding activity (4) failed to
increase Irf1 (Fig. 1I). In contrast, ectopic IRF8 expression in astro-
cytic A1 cells or neuronal Neuro2A cells failed to increase Irf1
transcripts (Fig. 1J and K), suggesting a cell-type-speciﬁc mecha-
nism. These results together suggest that gene expression of
microglial IRF1 is controlled by IRF8 and is dependent on its DNA
binding ability.
To determine the role of IRF1 in microglia, we employed IRF8-
transduced BV2 cells that have been shown to exhibit increased
expression of various microglial genes (4,11). We then investigated
the involvement of IRF1 in IRF8-mediated expression of microglial
genes by incorporating in BV2 cells a lentiviral vector that encoded
shRNA for Irf1 to knock down this gene expression (Fig. 2A). IRF8
transduction in BV2 cells caused upregulation of Irf1 expression
(Fig. 2A), as observed in primarymicroglial cells (Fig.1I). In addition,
IRF8-transduced cells without Irf1 shRNA increased the expression
of Tlr2, P2ry12, P2rx4, Cx3cr1, Il1b, Ctss, and Irf5 (Fig. 2B). Expression
of Aif1 that encodes ionized calcium binding adaptor molecule 1
(Iba1, a microglial marker) was also increased (Fig. 2B). The IRF8
transduction in A1 astrocytes or Neuro2A cells did not alter the gene
expressions (Fig. 2C), as is the case for Irf1 (Fig.1J and K). In contrast,
the knockdown of IRF1 in BV2 cells markedly attenuated IRF8-
Fig. 1. Interferon regulatory factor-8 (IRF8) regulates IRF1 expression in spinal cord and microglial cells (A) Quantitative real-time polymerase chain reaction (qRT-PCR)
analysis of Irf1, Irf2, IRF3 and Irf8 in total RNA extracted from spinal cord ipsilateral and contralateral to PNI before (naive) and after PNI. Values represent the relative ratio of genes
[normalized to the value for 18s ribosomal RNA (18s)] to the contralateral side of naive mice (n ¼ 6, ***P < 0.001). (B) qRT-PCR of Irf1, Irf2, and Irf3 in the spinal cords of wild-type
(WT) and IRF8-deﬁcient (Irf8/) mice 7 days after PNI. Values represent the relative ratio of genes (normalized to the value for 18s) to the contralateral side of WT mice (n ¼ 6,
***P < 0.001). (CeE) Double immunolabeling of IRF1 with CD11b (C), GFAP (D) and NeuN (E) in the dorsal spinal cord 7 days after PNI. Arrowheads indicate co-localization of IRF1
immunoﬂuorescence with that of CD11b (C) and GFAP (D). (F, G) Double immunolabeling of IRF1 with CD11b (F) and GFAP (G) in the ventral spinal cord 7 days after PNI. Arrowheads
indicate co-localization of IRF1 immunoﬂuorescence with that of CD11b (F) and GFAP (G). (H) Triple immunolabeling of IRF1 with IRF8 and GFAP in the ventral spinal cord 7 days
after PNI. White arrowhead indicates localization of IRF1 immunoﬂuorescence in an IRF8-negative cell labeled with GFAP. Orange arrowhead indicates co-localization of IRF1
immunoﬂuorescence with that of IRF8, but not GFAP. (I) qRT-PCR analysis of Irf1 in primary cultured microglial cells transduced with IRF8-green ﬂuorescent protein (GFP) (IRF8GFP),
IRF8(K79E)-GFP [IRF8(K79E)], or GFP alone (GFP). Values represent the relative ratio of Irf1 (normalized to the value for 18s) to the GFP-transduced cells (n ¼ 8, **P < 0.01). (J, K)
qRT-PCR analysis of Irf8 and Irf1 in (J) astrocytic A1 cells and (K) neuronal Neuro2A cells, transduced with IRF8-GFP or GFP. Values represent the relative ratio of genes (normalized
to the value for 18s) to the GFP-transduced cells (n ¼ 6, ***P < 0.001). Scale bars: 20 mm (CeH).
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the other genes (Fig. 2B). These results indicate that in microglia,
IRF8-induced IRF1 expression is crucial for the expression of IL-1b,
and to a lesser extent Iba1. To further investigate the role of IRF1 in
IL-1b expression, we lentivirally transduced IRF1 into microglial
cells and found that forced expression of IRF1 inWTmicroglial cells
caused a marked increase in Il1b expression (Fig. 2D). The Il1b
upregulation by IRF1 was blunted (but not completely abolished) in
Irf8/microglial cells (Fig. 2D). Together, these results suggest that
IRF1 plays a crucial role in regulating Il1b expression in microglia.
In the current study, we show that IRF8 is dependent on IRF1 to
activate the transcription of IL-1b in reactive microglia. Furthermore,
forced expression of IRF8 in cultured microglia induced de novo
expression of IRF1, although whether IRF8 directly binds to the
promoter loci of Irf1 to induce its expression remains to beelucidated. Furthermore, the lack of IRF8 totally suppressed the PNI-
induced IRF1 expression in the spinal cord. Considering the fact that
with in the spinal cord IRF8 expression is highly speciﬁc tomicroglia,
it is hypothesized that microglial IRF8 contributes to the PNI-
induced IRF1 expression not only in microglia but also in other
types of cells including astrocytes, presumably in a non-cell auton-
omous manner.
Given that expression pattern of Il1b in the spinal cord was
closely correlated with those of Irf1 and Irf8 after PNI (Fig. 2E) and
the PNI-induced Il1b expressionwasmarkedly suppressed in Irf8/
mice (4), our results suggest that IRF8-induced IRF1 expressionmay
play a role for the expression of IL-1b in spinal microglia. The
molecular machineries by which upregulated IRF1 contributes to
the expression of IL-1b remain to be elucidated. An early study has
shown that IRF8 forms a complex with other transcription factors
Fig. 2. IRF1 is required for IRF8-mediated expression of interleukin 1b (IL-1b) and ionized calcium binding adaptor molecule 1 (Iba1) in microglia (A, B) qRT-PCR analysis of
(A) Irf8 and Irf1, and (B) other microglial genes in IRF8-transduced BV2 cells with or without (control) Irf1 shRNA. Values represent the relative ratio of genes tested (normalized to
the value for 18s) to control shRNA-transduced cells (n ¼ 5e6, *P < 0.05, **P < 0.01, ***P < 0.001). (C) qRT-PCR analysis of Il1b and Aif1 in astrocytic A1 cells and neuronal Neuro2A
cells, transduced with IRF8-GFP or GFP. Values represent the relative ratio of genes (normalized to the value for 18s) to the GFP-transduced cells (n ¼ 6, ***P < 0.001). (D) qRT-PCR
analysis of Irf1 and Il1b mRNA in total RNA extracted from WT or Irf8/ primary cultured microglia transduced with IRF1 or GFP. Values represent the relative ratio of genes
(normalized to the value for 18s) to the GFP-transduced cells (n ¼ 6, *P < 0.05, **P < 0.01, ***P < 0.001). (E) qRT-PCR analysis of Il1b mRNA in total RNA extracted from spinal cord
ipsilateral and contralateral to PNI before (naive) and after PNI. Values represent the relative ratio of Il1b (normalized to the value for 18s) to the contralateral side of naive mice
(n ¼ 6, *P < 0.05, ***P < 0.001).
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interact with IRF1, which synergistically activates the expression of
target genes (12). Indeed, the upregulation of IL-1b mRNA in
cultured microglial cells by forced IRF1 expression was blunted in
Irf8/ microglial cells. Therefore, in IRF8-transduced microglial
cells, IRF1 might form a complex with IRF8 to increase Il1b
expression. However, our data showing that the effect of IRF1 on IL-
1b expression was not completely abolished in Irf8/ microglial
cells raise the possibility that increased IRF1 by itself may also has a
potential to increase the expression of IL-1b in microglia.
IL-1b has been shown to play multiple roles in CNS pathologies,
such as Alzheimer's disease, Parkinson's disease, and neuropathic
pain (5,6). Therefore, our results suggest that IRF8-IRF1 axis may be
a possible therapeutic target for the CNS diseases.Declaration of competing ﬁnancial interests
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